Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunocytochemistry and Immunohistochemistry01:22

Immunocytochemistry and Immunohistochemistry

14.3K
Immunocytochemistry (ICC) and immunohistochemistry (IHC) are techniques that use antibodies to check for specific proteins or antigens in a sample. The technique was first published by Albert Coons in 1941 to detect the presence of pneumococcal antigen in tissue sections from mice infected with Pneumococcus. Immunocytochemistry helps localization of proteins or antigens in individual cells like blood cells, stem cells, etc., while immunohistochemistry does the same for tissue samples.
These...
14.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel classification of testicular sex cord-stromal tumours from the Testicular Sex Cord-Stromal Tumour (TESST) group: a collaboration of the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathology (ISUP).

Histopathology·2026
Same author

Knowledge gaps in tubular gut tumours: a critical appraisal of the 6th edition of the World Health Organization classification of tumours.

The Journal of pathology·2026
Same author

HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer.

Oncogene·2026
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

Regulatory Guidance for the Return of Raw Genomic Data to Research Participants: A Qualitative Interview Study.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same author

Flexible and scalable federated learning with deep feature prompts for digital pathology.

NPJ digital medicine·2026

Related Experiment Video

Updated: Feb 27, 2026

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.6K

Next generation immunohistochemistry: Emerging substitutes to genetic testing?

Juliana Andrici1, Anthony J Gill2, Jason L Hornick1

  • 1Department of Pathology, Brigham and Women's Hospital & Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Seminars in Diagnostic Pathology
|July 1, 2017
PubMed
Summary

Immunohistochemistry (IHC) aids in identifying hereditary cancer predisposition syndromes by detecting mutations. Novel IHC markers offer promising tools for surgical pathologists to diagnose rare genetic cancer syndromes.

Keywords:
2SCBAP1BAP1 hereditary cancer predisposition syndromeCarney complexFAP-associated cribriform-morular variant of papillary thyroid carcinomaFamilial succinate dehydrogenase-related pheochromocytoma/paragangliomaFumarate hydrataseGlucagonHLRCCHPT-JTHRASQ61RMEN2Mahvash diseasePRKAR1APancreatic neuroendocrine tumor syndromeParafibrominSDHBβ-catenin

More Related Videos

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
10:57

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

11.3K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K

Related Experiment Videos

Last Updated: Feb 27, 2026

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.6K
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
10:57

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

11.3K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K

Area of Science:

  • Oncology
  • Pathology
  • Genetics

Background:

  • Hereditary cancer predisposition syndromes require early identification for effective screening and risk reduction.
  • Immunohistochemistry (IHC) is a valuable, cost-effective tool for detecting mutations in tumors and germlines associated with these syndromes.

Purpose of the Study:

  • To review novel immunohistochemistry (IHC) markers for diagnosing hereditary cancer predisposition syndromes.
  • To highlight the utility of IHC in complementing morphological and clinical assessments for surgical pathologists.

Main Methods:

  • Review of established and emerging IHC markers.
  • Focus on specific hereditary cancer syndromes including Carney complex, FAP, SDH-related tumors, HLRCC, MEN2, BAP1 syndrome, HPT-JT, and Pancreatic Neuroendocrine Tumor Syndrome.

Main Results:

  • Several IHC markers (PRKAR1A, β-catenin, SDHB, FH, 2SC, HRASQ61R, BAP1, parafibromin, glucagon) show potential for diagnosing specific hereditary cancer syndromes.
  • IHC can infer the presence of germline mutations, aiding in the identification of at-risk kindreds.

Conclusions:

  • Novel IHC markers are crucial for surgical pathologists in diagnosing hereditary cancer predisposition syndromes.
  • IHC facilitates the identification of at-risk families, enabling timely screening and risk-reduction strategies.